Login to Your Account

Other News To Note

Wednesday, March 21, 2012

• Convergence Pharmaceuticals Ltd., of Cambridge, UK, initiated a Phase II proof-of-concept study of CNV1014802 in pain associated with trigeminal neuralgia (TN). CNV1014802 is a small-molecule, state-dependent sodium channel blocker that exhibits potency and selectivity against the Nav1.7 sodium channel.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription